RE
MYGN icon

RBC Europe’s Myriad Genetics MYGN Stock Holding History

RBC Europe’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-125
Closed -$5.75K – 1131
2018
Q3 		$5.75K Hold
125
– – ﹤0.01% 946
2018
Q2 		$4.67K Hold
125
– – ﹤0.01% 977
2018
Q1 		$3.69K Hold
125
– – ﹤0.01% 998
2017
Q4 		$4.29K Buy
+125
New +$4.22K ﹤0.01% 981

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

RBC Europe's MYGN Position: Q4 2018 in Review

RBC Europe sold out of Myriad Genetics (MYGN) in Q4 2018, closing a stake of 125 shares — an estimated $5.75K sold.

RBC Europe first reported a position in MYGN in Q4 2017 and held it in 4 quarters. The position peaked at $5.75K in Q3 2018. 264 funds tracked by Wall St. Rank hold MYGN as of Q4 2018.

  • RBC Europe reported no remaining Myriad Genetics position as of Q4 2018 after selling out during the quarter.
  • RBC Europe sold 125 Myriad Genetics shares in Q4 2018, an estimated $5.75K.
  • RBC Europe first reported a position in Myriad Genetics in Q4 2017 and held it in 4 quarters.
  • RBC Europe's Myriad Genetics position peaked at $5.75K in Q3 2018.
  • 264 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2018.

Based on RBC Europe's 13F filing for Q4 2018, filed 9 Nov 2023.